KLL3: Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL)
Sponsor
Tampere University Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT01397916
Collaborator
(none)
73
1
10
7.3
Study Details
Study Description
Brief Summary
The Activity of Indoleamine 2,3-dioxygenase in patients with Chronic Lymphocytic Leukemia (CLL) is studied.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Detailed Description
The Activity of Indoleamine 2,3-dioxygenase in patients with Chronic Lymphocytic Leukemia (CLL)is studied in patients and healthly controls.
Study Design
Study Type:
Observational
Actual Enrollment
:
73 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
The Activity of Indoleamine 2,3-dioxygenase in Patients With Chronic Lymphocytic Leukemia (CLL)
Study Start Date
:
Feb 1, 2010
Actual Primary Completion Date
:
Dec 1, 2010
Actual Study Completion Date
:
Dec 1, 2010
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
CLL-patients
|
|
Controls
|
Outcome Measures
Primary Outcome Measures
- IDO activity and expression measured by kynurenine/tryptophan ratio in serum and by PCR in peripheral blood mononuclear cells. [3 months]
Indoleamine 2,3 -dioxygenase (IDO) activity in patients with CLL was measured by the serum kynurenine/tryptophan (kyn/trp) ratio and - the expression of INDO (encoding IDO enzyme) and INDOL1 (encoding IDO2 enzyme) genes in peripheral blood mononuclear cells via TaqMan real-time PCR.
Eligibility Criteria
Criteria
Ages Eligible for Study:
15 Years
to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
- Patients with CLL and lymphocyte count > 10 x 109/l
Exclusion Criteria:
- Acute infection
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Tampere university Hospital | Tampere | Finland | 33521 |
Sponsors and Collaborators
- Tampere University Hospital
Investigators
- Principal Investigator: Marjatta Sinisalo, MD, PhD, Tampere University Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
MSinisalo,
Dr,
Tampere University Hospital
ClinicalTrials.gov Identifier:
NCT01397916
Other Study ID Numbers:
- CLL-IDO
First Posted:
Jul 20, 2011
Last Update Posted:
Feb 23, 2022
Last Verified:
Feb 1, 2022
Keywords provided by MSinisalo,
Dr,
Tampere University Hospital
Additional relevant MeSH terms: